Connect with us
The Spanish pharma sector faced a downturn in the stock market in Q1 of 2024, with a collective market capitalization drop of 15.8% for six listed...
Almirall has acquired exclusive rights to Eloxx Pharmaceuticals' ZKN-013, a potentially promising treatment for rare dermatological diseases. Almirall gains global development and commercialization rights, paying Eloxx...
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition with its star drug. Rovi has...
The current project will last two years and will be financed by the Next Generation funds managed by the Center for Technological Development and Innovation (Cdti)...
Almirall collaborates with Microsoft to enhance dermatological innovation through AI techniques, improving data analysis, developing synthesizable molecules, and optimizing data management processes in drug discovery. The...
Almirall reduced its net profit by 58.3% until the third quarter of 2023, with a figure of €14.4 million, compared to the 34.5 million euros registered...
The gross margin of 64.9% has also been in line with expectations, reflecting the impact of the high cost of production goods and inflation that has...
Almirall is a global biopharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patient needs through science to improve their...
Almirall will obtain a license to use EpimAb's patented Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform. The Spanish pharmaceutical company reduced its profit by 56% in the first half...
Reig Jofre is the only one that does not follow the upward trend of the Spanish pharmaceutical sector and closes the third quarter with a decrease...